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Abstract
The determinants of clinical responses after autologous hematopoietic stem cell transplantation (aHSCT) in systemic
sclerosis (SSc) are still unraveled. We analyzed long-term immune reconstitution (IR) and T cell receptor (TCR)
repertoire diversity in 10 SSc patients, with at least 6 years simultaneous clinical and immunological follow-up after
aHSCT. Patients were retrospectively classified as long-term responders (A, n = 5) or non-responders (B, n = 5), using
modified Rodnan’s skin score (mRSS) and forced vital capacity (FVC%). All patients had similar severe SSc before
aHSCT. Number of reinjected CD34+ cells was higher in group B versus A (P = 0.02). Long-term mRSS fall >25% was
more pronounced in group A (P = 0.004), the only to improve long-term FVC% >10% (P = 0.026). There was an
overall trend toward increased of T cell reconstitution in group B versus A. B cells had a positive linear regression
slope in group A (LRS = 11.1) and negative in group B (LRS = −11.6). TCR repertoire was disturbed before aHSCT and
the percentage of polyclonal families significantly increased at long-term (P = 0.046), with no difference between
groups. Despite improved skin score after aHSCT in all SSc patients, pretransplant B cell clonal expansion and faster
post-transplant T cell IR in long-term non-responder/relapsing patients call for new therapeutic protocols guided by
IR analysis to improve their outcome.
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Introduction
Systemic sclerosis (SSc) is characterized by progressive fi-
brosis in the skin and internal organs [1], with 5-year mor-
tality rates up to 30% in rapidly progressive diffuse
cutaneous SSc (dcSSc) according to the extent of lung,
heart, and kidney involvement [2]. In severe SSc patients,
early European and North American phase I–II clinical
studies showed that autologous hematopoietic stem cell
transplantation (aHSCT) allowed rapid and durable re-
gression of skin and lung fibrosis [3, 4] with improved
functional status [5]. Results from the Autologous Stem
Cell Transplantation International Scleroderma (ASTIS)
multicenter randomized phase III trial demonstrated that
aHSCT confers better long-term survival than 12 monthly
intravenous pulses of cyclophosphamide in 156 early se-
vere dcSSc patients [6]. With around 1000 SSc patients
worldwide transplanted, aHSCT has become the best
treatment option for severe rapidly progressive SSc [7].
The rationale for treating autoimmune diseases (AD)
with aHSCT involves non-specific abrogation of autoreac-
tivity, mainly T and B cells, followed by reconstitution of a
more tolerant immune system and self-protective profile
[8, 9], in the ideal context that environmental triggering
factors will no longer be effective [10]. Studies in a few
AD patients showed that aHSCT acts differently from
standard immunosuppression, which modulates specific
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components of the autoimmunity process, while aHSCT
allows to reset the immune response and induces de novo
tolerance [7]. Therefore, immunological monitoring is a
key element of clinical follow-up post-transplant [11].
We had previously reported the early immune recon-
stitution (IR) profile associated with clinical remission
shortly and up to 1 year after high-dose cyclophospha-
mide and CD34+-selected aHSCT in seven SSc patients
[8]. Recovery of CD3+ T cell reconstitution was delayed
with persistent CD4+ T cell lymphopenia. NK cells
returned to normal within a month after transplant,
while circulating B cell levels were inversely associated
with clinical response, suggesting that pathogenic B cell
clones might preferentially expand if unfavorable out-
come [8]. Thereafter, Tsukamoto et al. found persistent
inversion of the Th2/Th1 ratio in eleven SSc patients
until 3 years post-aHSCT [12]. In a pilot study, we
reported restoration of Tregs and their suppressive
function 2 years after aHSCT in seven SSc patients
compared to controls [13], and partial fall of the pre-
transplant increase in pro-fibrotic and Th2-cytokines
serum levels [14]. Several questions remain, such as which
of the post-transplant IR mechanisms are most relevant to
warrant prolonged remission and what is the duration of
the immunological transplant-induced effects?
We therefore designed the present study to analyze the
long-term IR, using combined approaches of immunophe-
notyping and T cell receptor (TCR) diversity analysis
according to the observed clinical response in 10 SSc pa-
tients before and up to at least 6 years after aHSCT.
Methods
Study design and patients
We selected 10 SSc patients treated with aHSCT at Saint-
Louis Hospital (Paris, France) and for whom repeated
simultaneous clinical and immunological monitoring had
been obtained until long-term, at least 6 years, after
HSCT. All patients gave a written informed consent. They
had received CD34+-selected aHSCT, without or with
rabbit antithymocyte globulin (rATG, Genzyme) as part of
the previously published ISAMAIR [3] or ASTIS [6] pro-
tocols approved by the ethics committee. As a control
group, 18 healthy donors were tested to determine the ref-
erence values of TCR diversity.
Transplant procedure
Transplant procedure was previously described [3, 6]. In
brief, mobilization and collection of peripheral blood
hematopoietic stem cells (PBSC) using cyclophospha-
mide at 2 g/m2/day on two consecutive days followed
4 days later by rHu G-CSF (Lenograstim®, Aventis and
Chugai Pharma France) at 5 μg/kg/day subcutaneously
until the last apheresis. PBSC were collected when
CD34+ cells were above 20/μL in peripheral venous blood
and CD34+ cells were selected using immunomagnetic
bead technique (Nexel Isolex®300i Stem Cell Collection
System). Conditioning was performed at least 4 weeks
later, using cyclophosphamide at 50 mg/kg/day from day 5
to day 2 prior to CD34+-selected HSC reinjection without
or with rATG. All patients received rHu G-CSF after the
graft until neutrophil recovery.
Clinical follow-up before and after aHSCT
Clinical follow-up was performed as previously described
during the first year after aHSCT [8] and thereafter at
yearly intervals plus or minus 6 months. Clinical re-
sponse after aHSCT was assessed by the same observer
using repeated functional and physical examination of
organ involvement. Relapse was defined by any of the
following criteria [15]: an increase of skin score by 25%
from best improvement, as assessed by modified Rodnan
skin score (mRSS), or a decline in forced vital capacity
(FVC, %) by 10%, renal crisis, start of total parenteral
nutrition, or restarting of immune suppressive or modu-
lating medication. According to the clinical response at
long-term, SSc patients were retrospectively classified as
long-term responders (group A) and non-responders or
relapse or necessitating immunosuppression (group B)
within the first 6 years post-aHSCT. We analyzed their
IR profiles and evolution of TCR repertoire according to
the clinical outcome after aHSCT.
Immunomonitoring
At time of each clinical evaluation before and after
AHSCT, blood and serum samples were drawn for IR
analysis. Prospective lymphocyte immunophenotyping
was performed on freshly collected whole blood samples,
using a FACS Canto II flow cytometer and FACS DIVA
software (BD Biosciences, le Pont de Claix, France).
Absolute counts were determined using the TruCount
system (BD Biosciences) with BD Multitest (BD
Biosciences). Eight color labeling was performed with
the following mAbs: CD3, CD4, CD8, CD16, CD56,
CD45RA, CD45RO, and CD19. Data were analyzed
using FACS Diva (BD Biosciences). Anti-Scl-70 antibody
level detection was performed by enzyme-linked im-
munosorbent assay as previously described [8] and after
the year 2010 by BioPlex ANA Screen (Bio-Rad,
Hercules, CA).
T cell repertoire and clonality
Determination of TCR-Vβ usage was made from total
RNA using quantitative “Immunoscope” [8]. Briefly,
RNA was purified using TriReagent (Molecular Research
Center, Cincinnati, OH). Synthesis of complementary
DNA (cDNA), complementarity determining region 3
(CDR3) gene amplifications, run-off using an internal
β-chain gene constant fluorescent primer, gel running,
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and Immunoscope software analysis were performed [8].
The definition of Immunoscope profiles as polyclonal,
skewed, or negative was based on the identification of
peaks that deviate from the normal distribution curve [8].
Statistical analysis
All results are shown as mean ± standard deviation (SD).
Significant differences (P ≤ 0.05) between patient groups
related to individual conditions were assessed with Mann-
Whitney test and ANCOVA for general linear regression
analysis, using SPSS software. To reduce intra-group vari-
ability induced by individual differences at entry, we used
both mean absolutes values and percentages of the total
number of cells at inclusion that remained at each time
follow-up post-aHSCT for IR analysis, and global trends
were expressed using linear regression slope (LRS) [8].
Results
Patients clinical characteristics and response to aHSCT
Ten severe SSc patients, five males, mean age of
37.4 ± 13.9 years, were included in the study. According
to the observed clinical response during an overall mean
follow-up of 7.8 ± 0.8 years, five patients were long-term
responders (group A) and the five others (group B) had ei-
ther no response or clinical relapse or necessitated im-
munosuppression post-aHSCT. All were severe dcSSc
patients with similar functional status and organ involve-
ment before aHSCT. There was no clinical difference be-
tween groups A (n = 5) and B (n = 5) before transplant,
including for mRSS (28 ± 5.7 vs 31 ± 15.2, ns) and FVC%
(80 ± 22.2 vs 61 ± 8.8, ns) (Table 1). During the month
prior to transplant (baseline), patients received no treat-
ment (n = 6) or low dose oral steroids below or equal to
10 mg/day (n = 4). The individual patients’ graft character-
istics and engraftment duration after CD34+ aHSCT with-
out (n = 4) or with rATG (n = 6) are in Table 1. The
number of reinjected CD34+ cells was higher in group B
versus A (4.1 ± 1.3 vs 6.9 ± 2.0, P = 0.02), while time to
hematopoietic platelets and neutrophils reconstitution
were similar in both groups. After transplant, patients
received either no treatment up to long-term follow-
up (n = 5, group A) or mycophenolate mofetil 1–2 g/day
Table 1 Patients’ clinical characteristics (n = 10) with diffuse cutaneous systemic sclerosis (SSc) before autologous hematopoietic
stem cell transplantation (aHSCT) and graft characteristics at study inclusiona
Group A patients (n = 5) Group B patients (n = 5)
1 2 3 4 5 Mean (±SD) 1 2 3 4 5 Mean (±SD) Mean (±SD)
Patients characteristics at inclusion
Age, years 40 56 53 47 24 44 ± 12.7 24 27 52 19 32 30.8 ± 12.7 37.4 ± 13.9
Sex M M M F F – M M F F F – –
Disease duration, monthsb 6 18 29 20 18 18.2 ± 8.2 3 6 27 24 36 19.2 ± 14.1 18.7 ± 10.9
Steroids at inclusion, mg/day 7 10 0 10 0 5.4 ± 5.1 0 7 0 0 0 1.7 ± 3.5 3.8 ± 4.6
SHAQ (0–3) – 0.87 2.87 1.625 2 1.8 ± 0.8 1.25 2 – 2.125 0.16 1.4 ± 0.9 1.6 ± 0.8
mRSS (0–51) 26 22 37 29 25 27.8 ± 5.7 16 22 52 42 23 31 ± 15.2 29.4 ± 11.0
FVC, % 56 89 87 108 58 79.6 ± 22.2 52 72 63 56 – 60.7 ± 8.8 71.2 ± 19.3
DLCO, % predicted 45 75 72 56 48 59.2 ± 13.7 56 47 72 46 30 50.2 ± 15.4 54.7 ± 14.5
LVEF, % 58 82 62 61 73 67.2 ± 10.0 60 63 – 67 70 65 ± 4.4 66.2 ± 7.7
Serum creatinine, μmol/L 67 76 77 – 51 67.8 ± 12.0 52 73 60 59 71 63 ± 8.8 65.1 ± 10.0
CRP level, mg/L 62 2 15 20 2 20.2 ± 24.7 9 51 66 13 10 35 ± 27.8 26.8 ± 25.6
Anti-Scl-70 antibodies, U/ml 120 + 0 10.2 + 43.3 ± 66.5 0 + 39.1 130 21.3 47.6 ± 57.2 45.8 ± 55.8
Graft characteristics and engraftment duration
CD34+ cells × 106 infused/kgc 4.9 2.9 4.9 2.5 5.3 4.1 ± 1.3 5.8 6.3 5.19 8.79 7.2 6.9 ± 2.0 5.5 ± 2.2
CFU-GM cells × 104 infused/kgd 12.37 2.7 – – 88 34.3 ± 46.7 23 48 9.97 52.56 91 44.9 ± 31.2 40.9 ± 34.7
Days to 0.5 × 109 neutrophils/L 10 10 11 10 10 10.2 ± 0.4 10 7 10 9 9 9 ± 1.2 9.6 ± 1.1
Days to 20 × 109 platelets/L 8 10 10 9 7 8.8 ± 1.3 8 7 10 12 6 8.6 ± 2.4 8.7 ± 1.8
Days to 50 × 109 platelets/L 10 10 13 9 10 10.4 ± 1.5 9 7 Not reached 14 9 9.7 ± 3.0 10.1 ± 2.1
Anti Scl-70 (antitopoisomerase I) antibodies were measured by ELISA and quantified results expressed in arbitrary units (U/ml)
M male, F female, SHAQ Scleroderma Health Assessment Questionnaire, STE steroids, mRSS modified Rodnan skin thickness score, FVC forced vital capacity,
DLCO diffusing capacity for carbon monoxide, LVEF left ventricular ejection fraction, MUGA multiple gated acquisition scan, CRP C-reactive protein. + positive for
anti-Scl-70 antibodies
aSee the “Results” section for description of groups
bCalculated since first diagnosis of systemic sclerosis
cQuantity of CD34+ progenitor cells contained in the graft. CD34+ cell recovery after cryopreservation was 95% (range 75–100%)
dGM-CFUs/kg were counted on day 14 using a clonogenic progenitor assay as previously described[8]
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(n = 5, group B). Low-dose oral steroids below or equal to
10 mg/day were given in three out of five group A and B
patients. Compared to pretransplant mRSS values
(29 ± 11.0, n = 10), all SSc patients had a significant de-
crease in skin score at 1 year (19 ± 11.1, P = 0.029) which
was sustained until 6 years (8 ± 9.3, P = 0.006, Fig. 1a). The
significant regression of skin score, with a fall in mRSS
greater than 25% compared to pretransplant values, was
present in both groups throughout all follow-up (Fig. 1b)
and was significantly more pronounced at long-term in
group A than in group B patients (P = 0.004, Fig. 1b).
Compared to pretransplant FVC values (in % of normal,
Fig. 1c), there was no overall change in the lung function
post-aHSCT when considering all 10 SSc patients.
However, the relative FVC% changes compare to pre-
transplant values differed significantly between the two
groups during follow-up (P = 0.040, ANCOVA), and at
long-term, significant improvement of FVC above 10%
compared to pretransplant values was observed in group
A (P = 0.026, Fig. 1d).
Phenotypic analysis of lymphocyte populations after
HSCT
At inclusion, the absolute values of T cell subsets, CD4+,
CD4+CD45RA+, CD8+ T cells, and number of NK-cells
were in normal ranges for all patients and remained
stable after aHSCT with no difference between groups A
and B (Table 2). The absolute number of B cells was
lower in group A than in healthy donors (P < 0.05) and
was comparable to controls in group B (Table 2). Due to
lymphocyte counts variations between patients, we
expressed data as percentage of cells compared to
numbers before transplant. After aHSCT, there was an
overall trend toward increased CD3+ (LRS = 16.8) and
CD3+CD4+ (LRS = 12.5) T cell counts in group B com-
pared to group A (LRS = 8.7 and 9.7, respectively)
(Fig. 2a, b). A rapid increase in CD3+CD8+ T cell counts
starting 2–3 years post-transplant was observed in group
B (LRS = 21.8) patients although under immunosuppres-
sive drugs, while they remained almost stable in group A
(LRS = 5.0, Fig. 2c). The relative increase in the number
of CD4+CD45RA+ was higher in group B (LRS = 12.9)
than in group A (LRS = 2.6) patients (Fig. 2d). Memory
CD4+CD45RO+ T cell IR profiles were similar in groups
A (LRS = 7.2) and B (LRS = 10.5, Fig. 2e). The percentage
of B cell change differed with a sustained positive slope
in group A (LRS = 11.1), while the slope remained nega-
tive in group B (LRS = −11.6, Fig. 2f ). Four out of five
group A and three out of four group B patients seroposi-
tive for anti-Scl-70 before aHSCT became negative after
(Table 3). There was no correlation between B cell
counts and the presence of high levels of Scl-70 auto-
antibody (data not shown).
TCR repertoire diversity
TCR-Vβ family quantifications showed the same relative
usage of each family in all the 10 SSc patients before
and at long-term after transplantation as observed in
healthy subjects (Fig. 3a). As we [8] and others [16] pre-
viously reported in SSc patients, the TCR-Vβ family
usage did not differ from age-matched controls. CDR3
size distribution was very disturbed with few polyclonal
Fig. 1 Evolution of modified Rodnan skin score and pulmonary function before and until long-term follow-up (at least 6 years) after aHSCT in SSc
patients clinical groups. a Evolution of modified Rodnan skin score (mRSS) values in all patients (n = 10) from pre-transplant period (0 years) until
long-term follow-up (at least 6 years) after aHSCT. b mRSS percentage of change (mean ± SD) in the long-term responders (group A, n = 5) and
non-responders/relapsing (group B, n = 5) patients from pre-transplant period (baseline) until long-term follow-up (at least 6 years) after aHSCT.
Dashed line represents 25% improvement on mRSS. c Evolution of Forced Vital Capacity (FVC%) in all SSc patients (n = 10) from pre-transplant
period (0 years) until long-term follow-up (at least 6 years) after aHSCT. d Relative change in Forced Vital Capacity (FVC%) (mean ± SD) in the
long-term responders (group A, n = 5) and non-responders/relapsing (group B, n = 5) patients from pre-transplant period (baseline) until long-term
follow-up (at least 6 years) after aHSCT. Dashed lines represent improvement (+10%) or worsening (−10%) on FVC. aHSCT autologous hematopoietic
stem cell transplantation. *P < 0.05 at long-term time-point. **P < 0.01 at long-term timepoint
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Table 2 Phenotypic analysis of lymphocyte population in long-term responders (group A, n = 5) and non-responders/relapse or
necessitating immunosuppression (group B, n = 5) systemic sclerosis patients after autologous hematopoietic stem cell transplantation
Lymphocyte population Normal range
(cell counts/ml)
At inclusion 2–3 years 4–5 years Long term
Group A Group B Group A Group B Group A Group B Group A Group B
Total 1718–2620 1862 ± 764 1318 ± 748 1348 ± 777 1034 ± 584 1408 ± 937 1135 ± 482 1579 ± 616 1316 ± 624
T cells (CD3+) 1008–1647 1135 ± 485 957 ± 629 937 ± 569 713 ± 477 917 ± 561 749 ± 440 1417 ± 187 1143 ± 527
CD4 T cells (CD3+CD4+) 587–1009 730 ± 163 563 ± 373 409 ± 269 405 ± 305 510 ± 315 412 ± 269 678 ± 345 576 ± 367
Naive CD4 T cells
(CD4 + CD45RA+)
161–529 195 ± 161 145 ± 44 197 ± 171 152 ± 221 187 ± 193 158 ± 218 372 ± 175 290 ± 271
CD8 T cells (CD3+CD8+) 313–644 459 ± 182 345 ± 228 453 ± 259 282 ± 171 410 ± 245 299 ± 153 571 ± 39 443 ± 185
B cells (CD19+) 121–267 70 ± 53* 119 ± 91* 300 ± 391 137 ± 137 175 ± 56 208 ± 214 188 ± 63 197 ± 217
NK cells (CD3-CD16+CD56+) 82–340 176 ± 108 112 ± 34 151 ± 64* 92 ± 113* 115 ± 55 132 ± 100 150 ± 92 135 ± 101
Lymphocyte immonophenotyping was performed on fresh whole blood EDTA samples by direct eight-color immunofluorescence flow cytometry. Results are
expressed as absolute numbers (mean ± SD) of cell counts/ml
*P = 0.014 between the groups (two-tailed Mann-Whitney)
Fig. 2 Evolution of lymphocytes immune reconstitution during long-term follow-up (at least 6 years) after aHSCT in SSc patients clinical groups. Results
(mean ± SD) are expressed as percentages of the total numbers of lymphocytes at inclusion and the global trends of the immune reconstitution as
linear regression slope (LRS) in the long-term responders (group A, n = 5) and non-responders/relapsing (group B, n = 5) from pre-transplant period
(baseline) until long-term follow-up (at least 6 years) after aHSCT. a CD3+ total T cells. b CD3+CD4+ T cells. c CD3+CD8+ T cells. d CD4+CD45RA+ naïve
T cells. e CD4+CD45RO+ memory T cells. f CD19+ B cells
Farge et al. Journal of Hematology & Oncology  (2017) 10:21 Page 5 of 9
TCR-Vβ families and overexpression of skewed and/or
negative families (data not shown). At long-term, dis-
tinct changes in repertoire compared to pretransplant
TCR-Vβ profiles were observed (Fig. 3b). Two profiles
were noted, with either the recovery of a polyclonal
profile—similar to healthy individuals—as opposed to a
skewed and disturbed repertoire before transplant or the
persistence of disturbed profile with still oligoclonaly
expanded TCR-Vβ families (Fig. 3b). Overall, T cell
diversity improved in almost all long-term patients
compared to baseline, and the percentage of polyclonal
TCR-Vβ families increased significantly (P = 0.046)
with no significant difference between groups A and
B (Fig. 3c).
Table 3 Anti-scl-70 autoantibodies
Group A patients Group B patients
1 2 3 4 5 1 2 3 4 5
Anti-Scl-70 antibodies, U/ml
Baseline 120 +a 0 10.2 +a 0 +a 39.1 130 21.3
2–3 years 32.9 0 0 0 390 0 240 31.1 106.5 0
4–5 years 11.6 0 0 0 257 0 352 15.9 +a 0
Long term 0 0b 0b 0 >8b 0 3.8b >8b 250 0
Anti-Scl-70 antibodies were measured at pre-transplant period (baseline) and
sequentially during follow-up by enzyme-linked immunosorbent assay as
described in methods section. Quantified results are expressed in arbitrary
units/ml as previously published ([8])
aPositive for Anti-Scl-70 antibodies
bAnti-Scl-70 antibodies levels measured by BioPlex ANA Screen
Fig. 3 TCR-Vβ family expression and T cell receptor β-chain spectratyping before and at long-term after aHSCT. a Quantification of each TCR-Vβ
family at baseline (white bars) and at long-term (dark bars) after aHSCT in 10 dcSSc patients. Data are presented as mean ± SD. There are no differences
between the clinical groups. b TCR-Vβ chain third complementarity-determining region size distribution profile of selected families at baseline (pre, upper
level) and at long-term time point (lower level) for representative dcSSc patients who underwent autologous hematopoietic stem cell transplantation.
Left: Polyclonal distribution achievement at long-term time point post-HSCT from a skewed and disturbed repertoire at baseline (patient 3, group A,
responder). Right: Sustained disturbed distribution at long-term time point post-HSCT from a previously skewed profile at baseline (patient 1, group B,
non-responders or relapse or necessitating immunosuppression). c T cell repertoire diversity as measured by the percentage of polyclonal TCR-Vβ families
in all 10 dcSSc patients at baseline and at long-term follow-up (at least 6 years) after aHSCT
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Discussion
Early clinical follow-up of SSc patients after aHSCT has
shown rapid and significant improvement in mRSS [5]
and improved or stable FVC and DLco on lung function
tests [4, 5]. One year after transplant, clinical benefits
were such that the North American ASSIST trial closed
earlier, after enrollment of 19 instead of 60 SSc patients
initially powered, due to failure to reach equipoise
between aHSCT and the control group [4]. In the
European Society for Blood and Marrow Transplantation
(EBMT) ASTIS trial, despite increased treatment-related
mortality during the first year, treatment responses in
SSc clinical outcome variables 2 years after aHSCT were
higher than controls, allowing superior event-free and
overall survival rates until 10 years. While all SSc pa-
tients selected for transplant had severe disease at entry,
early clinical responses at 1 [5, 8] or 2 [6] years after
aHSCT as well as baseline cardiac function [15] were
shown to predict long-term clinical response.
In the present study, long-term clinical response was
not related to disease severity before aHSCT, contrary to
seven SSc patients previously analyzed for aHSCT re-
sponse at 1 year [8]. This may be related to improved
patient selection before transplant, while gaining know-
ledge in the field over the years and following updated
EBMT guidelines [7, 15]. Meaningful differences were
detected between the long-term responders and non-
responders/relapsing patients according to the trends in
early SSc clinical response and to global trends of IR. Of
note, long-term improvement in skin score was obtained
in all 10 patients with a mRSS fall >25%, which was
more pronounced in group A patients, who were the
only to improve FVC% above 10% after 6 years follow-
up. Interestingly, when the two groups of long-term pa-
tients were analyzed, the early clinical trends concerning
the relative improvements in mRSS and FVC (%) at
1 year after transplant became significant at long-term
after transplant. These data suggest that evolution of
clinical scores within the early years after transplant
indicate long-term clinical responses.
Depending on the conditioning regimen and the
underlying disease, several mechanisms contribute to
the IR process after aHSCT, which duration vary accord-
ing to individual patients [10]. During the early phase of
IR, the re-emergence of naïve T and B cells, the renewal
of the immune repertoire and reinstatement of synergis-
tic immunoregulatory mechanisms are expected [11],
but no study had yet evaluated the long-term IR after
aHSCT in SSc patients. We also aimed to clarify if main-
tenance or rapid reintroduction of immunosuppression
after transplant, as previously suggested [3], may im-
prove patient outcome despite no response or relapse.
In these 10 severe SSc patients followed for long term
after aHSCT, T, B, and NK cells were found within
normal ranges before transplantation [8, 12, 13]. After
aHSCT, the reconstitution of CD8+, CD4+CD45RA+,
CD4+CD45RO+ T, and NK cells was achieved after
2–3 years, confirming previous trends at 1 year [8]. The
relative increase in CD4+CD45RA+ after transplant
showed sustained activation of the immune system in
non-responders/relapsing patients. The same trends in IR
were observed for all T cell subtypes, and of note, the
CD3+CD8+ increase was steeper in the non-responders
as compared to the responder group. This may reflect the
persistence of an underlying disease mechanism in these
patients [8] and call for new therapeutic protocols after
transplant or use of adjuvant cellular therapy [3], such as
mesenchymal stromal cells infusion, in order to damper
the autoimmune and inflammatory response [17]. Delayed
CD4+ T cell recovery was more pronounced in group A
than in group B and was sustained at long-term. Further
studies will help to decipher the complex interplay be-
tween CD4+ T cell subsets and their influence on post-
transplant response in SSc and to better elucidate the role
of stem cell memory T cells during IR after aHSCT [18].
Our results also suggest that pathogenic B cell clones
preferentially expand before transplant in these SSc pa-
tients with less favorable outcome at 1 year and there-
after, as previous reported [8]. There was no correlation
between the B cell counts and the anti-scl-70 autoanti-
body levels after aHSCT. However, four out five from
group A patients and only one out five from group B pa-
tients became seronegative for anti-scl-70 at long-term,
illustrating sustained autoimmunity in non-responders
or relapsing patients despite reintroduction for immuno-
suppressive drugs. Nonetheless, the responder patients
presented a sustained and positive B cell reconstitution
slope, which underlines the need for further refined ana-
lysis of the respective number and function of the differ-
ent B cells subsets, notably the regulatory B cells.
The TCR-Vβ repertoire at baseline was disturbed in all
dcSSc patients compared to controls, with a higher
number of families presenting a skewed and oligoclonaly
expanded profile as previously reported [8, 16]. Here, we
show sustained and higher clonal diversity of the TCR
repertoire at long-term after transplant in both groups,
irrespective of their long-term clinical response. Some
oligoclonally expanded families were still found at
long-term after transplant both in group A and B pa-
tients, indicating that either the patients residual T
cells survived the conditioning or were re-infused
with the graft at time of aHSCT and can persist for
long term or that thymic rebound was not appro-
priately achieved. As thymic reactivation participate to
the observed clinical response after aHSCT [8–10, 19],
adjuvant therapies to support hematopoiesis and thymic
output could be helpful to improve long-term clinical re-
sponse [17, 20, 21].
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In conclusion, despite improved skin score early
after transplant in all SSc patients, pretransplant B
cell clonal expansion and faster T cells IR after
aHSCT were specific to long-term non-responder/
relapsing patients. Immune reconstitution analysis will
guide the clinicians for establishing new therapeutic pro-
tocols in long-term non-responding/relapsing patients
after HSCT.
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